Skip to main navigation Skip to search Skip to main content

A Two Part, Phase 1/2, Safety, PK and PD study of TOL101, an anti-TCR Monoclonal Antibody for Prophylaxis of Acute Organ Rejection in Patients Receiving Renal Transplantation

Project: Research

Project Details

StatusFinished
Effective start/end date06/15/11 → 06/14/16

Funding

  • Tolera Therapeutics: $7,000.00